An inverse correlation between serum 25-hydroxyvitamin D concentration and atopic dermatitis (AD) severity has been suggested.
To determine if a statistically significant relationship exists between serum 25-hydroxyvitamin D concentration and AD severity.
A cross-sectional study was conducted of patients with AD who were 1 to 18 years of age. An objective Severity Scoring of Atopic Dermatitis (SCORAD) and a serum 25-hydroxyvitamin D concentration were measured for each subject. Statistical analysis was performed using appropriate univariate tests and multivariable models.
Ninety-four of 97 enrolled subjects were included in the analysis. Vitamin D deficiency (25-hydroxyvitamin D <20 ng/mL) was present in 37 subjects (39%), insufficiency (25-hydroxyvitamin D 21-29 ng/mL) in 33 (35%), and sufficiency (25-hydroxyvitamin D ≥30 ng/mL) in 24 (26%). The correlation between 25-hydroxyvitamin D concentration and SCORAD was not significant (r = –0.001; P = .99). A multivariate model showed that a lower serum 25-hydroxyvitamin D concentration was significantly associated with age 3 years or older (P < .0001), black race (P < .0001), and winter season (P = .0084).
Limitations of this study include the inability to control for natural sunlight exposure, vitamin D intake, and AD treatment; in addition, only a single time point was captured.
Serum 25-hydroxyvitamin D concentration is not significantly correlated with AD severity in our pediatric population.Le texte complet de cet article est disponible en PDF.
Key words : asthma, atopic dermatitis, atopy, eczema, 25-hydroxyvitamin D, vitamin D
Abbreviations used : 1,25(OH)2D, 25(OH)D, AD, SCORAD
| Funding sources: This project was supported in part by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health (NIH), through grant number UL1RR031973. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. Additional support was received from the Russell and Betty Jane Shaw Fund of the Greater Milwaukee Foundation.
| Disclosure: Dr Galbraith serves on an advisory board for Valeant Pharmaceuticals.
| This work has previously been presented in poster format at the 38th Annual Meeting of the Society for Pediatric Dermatology.
| Conflicts of interest: None declared.